Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Molecules ; 23(12)2018 Nov 28.
Artigo em Inglês | MEDLINE | ID: mdl-30487471

RESUMO

Berberine (BBR), a natural isoquinoline alkaloid derived from Chinese herbs, exerts many biological effects, including antiviral, antimicrobial, antidiarrhea, anti-inflammatory, and antitumor effects. In this study, a novel berberine nanoparticle (NP) consisting of heparin (HP) and BBR with or without being shelled with linear polyethyleneimine (LPEI) was developed to enhance its antitumor activity on osteosarcoma U-2 OS cells. With varying ratios of HP to BBR, HP/BBR NPs had a size ranging from 218.4 ± 3.9 to 282.0 ± 5.1 nm and zeta potential from -35.7 ± 0.4 to -51.9 ± 1.8 mV. After shelling with LPEI, the resultant NPs (HP/BBR/LPEI) possessed a size ranging from 226.3 ± 3.0 to 405.7 ± 85.2 nm and zeta potential from -46.5 ± 0.3 to -35.6 ± 0.5 mV; the encapsulation rate of BBR was close to 80%. The release profiles of both NPs were revealed to be slower than that of BBR solution. Results also showed that BBR and its two derived NPs reduced the viability of U-2 OS cells, and BBR NPs increased the cellular uptake of BBR. Cells were arrested at the G1 phase when treated individually with BBR and the two NPs (HP/BBR and HP/BBR/LPEI) and DNA condensation was induced. In addition, BBR and BBR NPs reduced the expression of mouse double minute 2 homolog (MDM2) but increased that of p53, and BBR NPs enhanced apoptotic effects. In short, heparin-based nanoparticles could be potential carriers for osteosarcoma treatment.


Assuntos
Antineoplásicos , Berberina , Neoplasias Ósseas/tratamento farmacológico , Portadores de Fármacos , Heparina , Nanopartículas , Osteossarcoma/tratamento farmacológico , Polietilenoimina , Antineoplásicos/química , Antineoplásicos/farmacologia , Berberina/química , Berberina/farmacologia , Neoplasias Ósseas/metabolismo , Neoplasias Ósseas/patologia , Portadores de Fármacos/química , Portadores de Fármacos/farmacologia , Heparina/química , Heparina/farmacologia , Humanos , Nanopartículas/química , Nanopartículas/uso terapêutico , Osteossarcoma/metabolismo , Osteossarcoma/patologia , Polietilenoimina/química , Polietilenoimina/farmacologia
2.
Molecules ; 22(1)2017 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-28054985

RESUMO

The efficient delivery of sufficient amounts of nucleic acids into target cells is critical for successful gene therapy and gene knockdown. The DNA/siRNA co-delivery system has been considered a promising approach for cancer therapy to simultaneously express and inhibit tumor suppressor genes and overexpressed oncogenes, respectively, triggering synergistic anti-cancer effects. Polyethylenimine (PEI) has been identified as an efficient non-viral vector for transgene expression. In this study, we created a very high efficient DNA/siRNA co-delivery system by incorporating a negatively-charged poly-γ-glutamic acid (γ-PGA) into PEI/nucleic acid complexes. Spherical nanoparticles with about 200 nm diameter were formed by mixing PEI/plasmid DNA/siRNA/γ-PGA (dual delivery nanoparticles; DDNPs) with specific ratio (N/P/C ratio) and the particles present positive surface charge under all manufacturing conditions. The gel retardation assay shows both nucleic acids were effectively condensed by PEI, even at low N/P ratios. The PEI-based DDNPs reveal excellent DNA/siRNA transfection efficiency in the human hepatoma cell line (Hep 3B) by simultaneously providing high transgene expression efficiency and high siRNA silencing effect. The results indicated that DDNP can be an effective tool for gene therapy against hepatoma.


Assuntos
Nanopartículas/química , Plasmídeos/metabolismo , Polietilenoimina/química , Ácido Poliglutâmico/análogos & derivados , RNA Interferente Pequeno/genética , Transfecção/métodos , Transporte Biológico , Linhagem Celular Tumoral , Expressão Gênica , Inativação Gênica , Genes Reporter , Proteínas de Fluorescência Verde/antagonistas & inibidores , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Hepatócitos/citologia , Hepatócitos/metabolismo , Humanos , Proteínas Luminescentes/antagonistas & inibidores , Proteínas Luminescentes/genética , Proteínas Luminescentes/metabolismo , Nanopartículas/ultraestrutura , Plasmídeos/química , Ácido Poliglutâmico/química , RNA Interferente Pequeno/química , RNA Interferente Pequeno/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...